scispace - formally typeset
Open AccessJournal ArticleDOI

Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.

Reads0
Chats0
TLDR
A formulation with a 1:25 ratio of RBD219-N1 to Alhydrogel® provided high neutralizing antibody titers, 100% protection with non-detectable viral loads with minimal or no eosinophilic pulmonary infiltrates, and this vaccine formulation is under consideration for further development against SARS-CoV and potentially other emerging and re-emerging beta-CoVs such as SARS -CoV-2.
About
This article is published in Vaccine.The article was published on 2020-11-03 and is currently open access. It has received 73 citations till now. The article focuses on the topics: Neutralizing antibody & Viral Vaccine.

read more

Citations
More filters
Journal ArticleDOI

The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens.

TL;DR: This review highlights and describes the recent progress that has been made in the biosynthesis, structure, function, and antigenicity of the SARS-CoV-2 S glycoprotein, aiming to provide valuable insights into the design and development ofThe S protein-based vaccines as well as therapeutics.
Journal ArticleDOI

Prospects for a safe COVID-19 vaccine.

TL;DR: Evaluated research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease finds neither principles of immunity nor preclinical studies provide a basis for prioritizing among the CO VID-19 vaccine candidates with respect to safety.
Journal ArticleDOI

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.

TL;DR: Wang et al. as mentioned in this paper reviewed the different types of vaccines designed and developed against SARS-CoV-2, placing emphasis on whether they are based on the complete S glycoprotein, its antigenic domains such as the receptor-binding domain (RBD) or short epitopes within the S gly coprotein.
Journal ArticleDOI

COVID-19 vaccine development: milestones, lessons and prospects

TL;DR: In this article , the safety and efficacy of COVID-19 vaccines were evaluated, including the possible complications and different effects on pregnant women, the elderly, people with immune diseases and acquired immunodeficiency syndrome (AIDS), transplant recipients, and cancer patients.
References
More filters
Journal ArticleDOI

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

TL;DR: The clinical picture was remarkably similar to that of the severe acute respiratory syndrome (SARS) outbreak in 2003 and reminds us that animal coronaviruses can cause severe disease in humans.
Journal ArticleDOI

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

TL;DR: Recent advances in the development of vaccines and therapeutics based on the S protein are highlighted, which plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV.
Journal ArticleDOI

Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003

TL;DR: Genetic analysis showed that the SARS CoV isolates from Guangzhou shared the same origin with those in other countries, and had a phylogenetic pathway that matched the spread of SARS to the other parts of the world.
Related Papers (5)